What is Atomic AI?
Atomic AI is at the forefront of AI-driven RNA drug discovery, leveraging advanced machine learning and structural biology to pioneer RNA-targeted small molecules and RNA-based medicines. Their sophisticated research and development platform integrates state-of-the-art deep learning models with in-house wet-lab assays, accelerating the identification of potent and selective therapeutics. The company's mission is to tackle critical health challenges by developing novel treatments, positioning itself as a key partner for pharmaceutical companies and research institutions seeking cutting-edge drug development solutions.
How much funding has Atomic AI raised?
Atomic AI has raised a total of $35M across 1 funding round:
Series A
$35M
Series A (2023): $35M with participation from Greylock Partners, 8VC, Playground, The Factory HQ, and AME Cloud Ventures
Key Investors in Atomic AI
Greylock Partners
Greylock Partners is a venerable venture capital firm with a focus on early-stage technology companies, particularly in sectors like AI, enterprise software, and cybersecurity. Their extensive experience includes backing market-defining companies such as Airbnb and Facebook.
8VC
8VC is a technology investment firm that backs visionary teams and industry-transforming companies, with partners who have a strong background as founders and operators. They primarily invest in smart enterprise platforms across various industries, including healthcare and Bio-IT.
Playground
Playground Global invests in founders utilizing frontier technologies to build businesses with significant impact, focusing on areas such as artificial intelligence, life sciences, and next-gen compute. They provide expertise to help early-stage entrepreneurs achieve their potential.
What's next for Atomic AI?
With this substantial strategic investment, Atomic AI is poised for significant expansion and acceleration of its drug discovery pipeline. The Series A financing indicates a transition from early-stage development to a scaling phase, enabling the company to further refine its AI platform, expand its research capabilities, and advance its therapeutic candidates toward clinical trials. This capital injection will be instrumental in solidifying Atomic AI's market position and driving its long-term growth objectives in the competitive biotechnology sector.
See full Atomic AI company page
